# US 2021/0277075 A1 · Animal-free dietary collagen > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0277075 A1 - Document ID: US20210277075A1 - Status: Published application - Kind: A1 - Application number: 17/171,874 - Filed: 2021-02-09 - Published: 2021-09-09 - Earliest claimed: 2020-01-24 - Assignees: Geltor, Inc. - Applicants: Geltor, Inc. - Inventors: Nikolay OUZOUNOV; Jeffrey R. MELLIN; Julia CO - Web page: https://patentgrep.com/patent/US20210277075A1 ## CPC - A23L 2/66: Proteins - C07K 14/47: from mammals - A21D 2/264: {Vegetable proteins} - A23L 2/39: Dry compositions - A23L 33/18: Peptides; Protein hydrolysates - A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula} - A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 17/16: Emollients or protectives, e.g. against radiation - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61Q 19/08: Anti-ageing preparations - C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] - A61Q 3/00: Manicure or pedicure preparations - A61Q 19/02: for chemically bleaching or whitening the skin - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A21D: TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS (preservation of flour or dough before baking A23B40/00; preservation of bakery products A23B45/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS ## Abstract Provided herein are non-naturally occurring polypeptides comprising a sequence of a fragment of a collagen and recombinant cells containing heterologous nucleic acid sequences encoding the non-naturally occurring polypeptides. Further provided herein are animal-free methods of generating and purifying such non-naturally occurring polypeptides using microorganisms, preferably from bacterial cells. ## Claims ### Claim 1 A non-naturally occurring polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 31 with an N-terminal truncation, a C-terminal truncation, or both. ### Claim 2 (depends on 1) The non-naturally occurring polypeptide of claim 1, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 31 with an N-terminal truncation, a C-terminal truncation, or both. ### Claim 3 (depends on 1) The non-naturally occurring polypeptide of claim 1, comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 31 with an N-terminal truncation, a C-terminal truncation, or both. ### Claim 4 (depends on 1) The non-naturally occurring polypeptide of claim 1, comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 31 with an N-terminal truncation, a C-terminal truncation, or both. ### Claim 5 (depends on 1) The non-naturally occurring polypeptide of claim 1, comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 31 with an N-terminal truncation, a C-terminal truncation, or both. ### Claim 6 (depends on 1) The non-naturally occurring polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO: 31 with an N-terminal truncation, a C-terminal truncation, or both. ### Claim 7 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the N-terminal truncation is an N-terminal truncation of 50 amino acids to 600 amino acids. ### Claim 8 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the C-terminal truncation is a C-terminal truncation of 50 amino acids to 250 amino acids. ### Claim 9 (depends on 1) The non-naturally occurring polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 6. ### Claim 10 (depends on 1) The non-naturally occurring polypeptide of claim 1, consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 6. ### Claim 11 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide has a total truncation of 50 amino acids to 900 amino acids. ### Claim 12 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide is 50 amino acids to 250 amino acids in length. ### Claim 13 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide does not comprise one or more of: a laminin G domain, a Von Willebrand factor type A (vWA) domain, and a fibrillar collagen C-terminal domain. ### Claim 14 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide comprises one or more collagen triple helix repeats. ### Claim 15 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide is monomeric. ### Claim 16 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide does not form a stable triple helix structure of a naturally occurring collagen. ### Claim 17 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide is substantially free of other collagen chains. ### Claim 18 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide has a non-naturally occurring level of hydroxylation relative to a naturally-occurring collagen. ### Claim 19 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein fewer than 10% of prolines present in the non-naturally occurring polypeptide are hydroxylated. ### Claim 20 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide is non-hydroxylated. ### Claim 21 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide has a non-naturally occurring level of glycosylation relative to a naturally-occurring collagen. ### Claim 22 (depends on 1) The non-naturally occurring polypeptide of claim 1, wherein the non-naturally occurring polypeptide protein comprises less than 5 wt. % glycosylation. ### Claim 23 (depends on 1) A composition comprising the non-naturally occurring polypeptide of claim 1, wherein the composition is a product formulated for consumption by an individual. ### Claim 24 (depends on 23) The composition of claim 23, wherein the product is a food, a beverage, or a nutraceutical supplement, and wherein the non-naturally occurring polypeptide is an ingredient present in the product in a concentration of at least about 0.1% w/w. ### Claim 25 (depends on 23) The composition of claim 23, wherein the product is a powder, and wherein the non-naturally occurring polypeptide is at least about 50% w/w of the powder. ### Claim 26 (depends on 23) A method of improving the appearance of the skin, the hair, and/or the nails of a subject, and/or improving bone, muscle, and/or joint health in the subject, the method comprising: administering to the subject a composition of claim 23. ### Claim 27 (depends on 26) The method of claim 26, wherein the administering comprises orally administering to the subject. ### Claim 28 (depends on 1) A recombinant cell containing therein at least one copy of a heterologous nucleic acid sequence encoding a non-naturally occurring polypeptide of claim 1. ### Claim 29 (depends on 28) The recombinant cell of claim 28, wherein the recombinant cell lacks an enzyme that hydroxylates one or more amino acids of the non-naturally occurring polypeptide.